INSYS Therapeutics Inc: Neoplasms trials
The registry lists 12 Neoplasms studies with INSYS Therapeutics Inc as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 10Phase 2 1Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer PainCompletedNCT00538863Phase 3Results posted
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3Results posted
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced CancerCompletedNCT00100672Phase 1
- Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced CancerCompletedNCT00100139Phase 1
- Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced CancerCompletedNCT00080418Phase 1
- Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced CancerCompletedNCT00046540Phase 1
- Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00041587Phase 1/2
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six DosesWithdrawnNCT00024687Phase 1
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 DaysWithdrawnNCT00024674Phase 1
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid TumorsCompletedNCT00024661Phase 1
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced MalignanciesCompletedNCT00024648Phase 1
- Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced CancerCompletedNCT00024492Phase 1